Valuation: Tvardi Therapeutics, Inc.

Market Cap 15.34M 13.63M 12.72M 11.59M 21.87M 1.47B 22.07M 154M 59.65M 754M 57.59M 56.34M 2.42B P/E 2026 *
-0.52x
P/E 2027 * -0.51x
Enterprise Value 15.34M 13.63M 12.72M 11.59M 21.87M 1.47B 22.07M 154M 59.65M 754M 57.59M 56.34M 2.42B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
75.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tvardi Therapeutics, Inc.

1 day-0.80%
1 week-2.36%
Current month-0.80%
1 month-32.97%
3 months-38.61%
6 months-58.94%
Current year-71.16%
1 week 1.13
Extreme 1.13
1.42
1 month 0.93
Extreme 0.93
2
Current year 0.93
Extreme 0.93
5.69
1 year 0.93
Extreme 0.93
43.65
3 years 0.93
Extreme 0.93
43.65
5 years 0.93
Extreme 0.93
43.65
10 years 0.93
Extreme 0.93
43.65
Date Insider Type Main position Quantity % Market Cap. Importance
6/9/26 A Free

Chairman

6,000 0.0640%
1/29/26 A Free

Chief Executive Officer

115,000 1.2258%
1/29/26 A Free

Chief Technology Officer

45,000 0.4797%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-2.36%-96.92% - 15.34M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.28%-0.76%+37.68%+128.54% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.95%+138.26%

Financials

2026 *2027 *
Net sales - -
Net income -25.97M -23.07M -21.53M -19.63M -37.02M -2.5B -37.36M -261M -101M -1.28B -97.49M -95.37M -4.1B -35.88M -31.88M -29.76M -27.12M -51.15M -3.45B -51.63M -360M -140M -1.76B -135M -132M -5.66B
Net Debt - -
Logo Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Employees
12
Date Price Change Volume
02/10/26 $1.150 -7.26% 313,810
01/10/26 $1.240 -0.80% 332,652
30/09/26 $1.250 -2.34% 232,689
29/09/26 $1.280 -3.76% 254,083
28/09/26 $1.330 +4.72% 351,438
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.150USD
Average target price
9.250USD
Spread / Average Target
+704.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TVRD Stock